Rigel Pharmaceuticals Inc (RIGL)

$0.9224

+0.01

(+0.92%)▲

Market is closed - opens 7 PM, 23 May 2024

Insights on Rigel Pharmaceuticals Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 35.79M → 29.53M (in $), with an average decrease of 17.5% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 737.0K → -8.24M (in $), with an average decrease of 1219.0% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 58.5% return, outperforming this stock by 99.1%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 232.5% return, outperforming this stock by 307.5%

Performance

  • $0.90
    $0.95
    $0.92
    downward going graph

    2.14%

    Downside

    Day's Volatility :5.69%

    Upside

    3.62%

    downward going graph
  • $0.71
    $1.77
    $0.92
    downward going graph

    22.61%

    Downside

    52 Weeks Volatility :59.77%

    Upside

    48.02%

    downward going graph

Returns

PeriodRigel Pharmaceuticals IncSector (Health Care)Index (Russel 2000)
3 Months
-29.69%
-0.6%
0.0%
6 Months
-3.8%
12.1%
0.0%
1 Year
-40.65%
11.3%
0.0%
3 Years
-74.89%
17.6%
-20.1%

Highlights

Market Capitalization
167.5M
Book Value
- $0.18
Earnings Per Share (EPS)
-0.11
PEG Ratio
-0.1
Wall Street Target Price
4.53
Profit Margin
-16.61%
Operating Margin TTM
-23.59%
Return On Assets TTM
-7.91%
Return On Equity TTM
-699.05%
Revenue TTM
119.2M
Revenue Per Share TTM
0.68
Quarterly Revenue Growth YOY
13.3%
Gross Profit TTM
53.7M
EBITDA
-14.6M
Diluted Eps TTM
-0.11
Quarterly Earnings Growth YOY
-0.48
EPS Estimate Current Year
-0.07
EPS Estimate Next Year
0.07
EPS Estimate Current Quarter
-0.03
EPS Estimate Next Quarter
-0.02

Analyst Recommendation

Buy
    58%Buy
    41%Hold
    0
    0%Sell
Based on 12 Wall street analysts offering stock ratings for Rigel Pharmaceuticals Inc(by analysts ranked 0 to 5 stars)
Based on 12 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
7
7
7
Hold
5
5
5
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 391.11%

Current $0.92
Target $4.53

Company Financials

FY18Y/Y Change
Revenue
44.5M
↑ 892.62%
Net Income
-70.5M
↓ 9.63%
Net Profit Margin
-158.35%
↑ 1580.99%
FY19Y/Y Change
Revenue
59.3M
↑ 33.2%
Net Income
-66.5M
↓ 5.58%
Net Profit Margin
-112.24%
↑ 46.11%
FY20Y/Y Change
Revenue
108.6M
↑ 83.21%
Net Income
-30.4M
↓ 54.33%
Net Profit Margin
-27.98%
↑ 84.26%
FY21Y/Y Change
Revenue
149.2M
↑ 37.39%
Net Income
-17.9M
↓ 41.05%
Net Profit Margin
-12.0%
↑ 15.98%
FY22Y/Y Change
Revenue
120.2M
↓ 19.43%
Net Income
-61.6M
↑ 243.84%
Net Profit Margin
-51.23%
↓ 39.23%
FY23Y/Y Change
Revenue
116.9M
↓ 2.79%
Net Income
-25.1M
↓ 59.27%
Net Profit Margin
-21.47%
↑ 29.76%
Q4 FY22Q/Q Change
Revenue
51.3M
↑ 128.82%
Net Income
723.0K
↓ 103.68%
Net Profit Margin
1.41%
↑ 89.19%
Q1 FY23Q/Q Change
Revenue
26.1M
↓ 49.16%
Net Income
-14.3M
↓ 2084.37%
Net Profit Margin
-55.03%
↓ 56.44%
Q2 FY23Q/Q Change
Revenue
26.9M
↑ 3.13%
Net Income
-6.6M
↓ 54.0%
Net Profit Margin
-24.55%
↑ 30.48%
Q3 FY23Q/Q Change
Revenue
28.1M
↑ 4.64%
Net Income
-5.7M
↓ 13.76%
Net Profit Margin
-20.23%
↑ 4.32%
Q4 FY23Q/Q Change
Revenue
35.8M
↑ 27.22%
Net Income
737.0K
↓ 112.95%
Net Profit Margin
2.06%
↑ 22.29%
Q1 FY24Q/Q Change
Revenue
29.5M
↓ 17.48%
Net Income
-8.2M
↓ 1219.0%
Net Profit Margin
-27.92%
↓ 29.98%
FY18Y/Y Change
Total Assets
139.1M
↑ 16.79%
Total Liabilities
29.2M
↑ 58.31%
FY19Y/Y Change
Total Assets
147.6M
↑ 6.08%
Total Liabilities
93.8M
↑ 220.72%
FY20Y/Y Change
Total Assets
110.4M
↓ 25.2%
Total Liabilities
76.4M
↓ 18.56%
FY21Y/Y Change
Total Assets
167.3M
↑ 51.6%
Total Liabilities
137.0M
↑ 79.37%
FY22Y/Y Change
Total Assets
134.3M
↓ 19.75%
Total Liabilities
147.9M
↑ 7.99%
FY23Y/Y Change
Total Assets
117.2M
↓ 12.7%
Total Liabilities
145.9M
↓ 1.37%
Q4 FY22Q/Q Change
Total Assets
134.3M
↑ 16.15%
Total Liabilities
147.9M
↑ 9.19%
Q1 FY23Q/Q Change
Total Assets
123.6M
↓ 7.94%
Total Liabilities
147.9M
↓ 0.02%
Q2 FY23Q/Q Change
Total Assets
117.1M
↓ 5.28%
Total Liabilities
145.2M
↓ 1.8%
Q3 FY23Q/Q Change
Total Assets
115.3M
↓ 1.51%
Total Liabilities
147.2M
↑ 1.34%
Q4 FY23Q/Q Change
Total Assets
117.2M
↑ 1.65%
Total Liabilities
145.9M
↓ 0.88%
Q1 FY24Q/Q Change
Total Assets
126.5M
↑ 7.93%
Total Liabilities
158.2M
↑ 8.45%
FY18Y/Y Change
Operating Cash Flow
-58.8M
↓ 24.15%
Investing Cash Flow
25.0M
↓ 228.2%
Financing Cash Flow
71.9M
↓ 38.91%
FY19Y/Y Change
Operating Cash Flow
-41.5M
↓ 29.44%
Investing Cash Flow
-23.7M
↓ 194.76%
Financing Cash Flow
11.4M
↓ 84.19%
FY20Y/Y Change
Operating Cash Flow
-52.2M
↑ 25.72%
Investing Cash Flow
47.5M
↓ 300.65%
Financing Cash Flow
12.6M
↑ 10.61%
FY21Y/Y Change
Operating Cash Flow
5.9M
↓ 111.26%
Investing Cash Flow
-80.0M
↓ 268.62%
Financing Cash Flow
62.7M
↑ 398.57%
FY22Y/Y Change
Operating Cash Flow
-73.8M
↓ 1354.81%
Investing Cash Flow
72.8M
↓ 190.93%
Financing Cash Flow
6.6M
↓ 89.55%
Q4 FY22Q/Q Change
Operating Cash Flow
-21.9M
↑ 64.72%
Investing Cash Flow
18.6M
↑ 77.89%
Financing Cash Flow
-2.1M
↓ 138.03%
Q1 FY23Q/Q Change
Operating Cash Flow
-4.1M
↓ 81.4%
Investing Cash Flow
777.0K
↓ 95.82%
Financing Cash Flow
19.1M
↓ 1012.36%
Q2 FY23Q/Q Change
Operating Cash Flow
5.9M
↓ 245.56%
Investing Cash Flow
3.0M
↑ 282.24%
Financing Cash Flow
-373.0K
↓ 101.95%

Technicals Summary

Sell

Neutral

Buy

Rigel Pharmaceuticals Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Rigel Pharmaceuticals Inc
Rigel Pharmaceuticals Inc
-19.12%
-3.8%
-40.65%
-74.89%
-55.41%
Moderna, Inc.
Moderna, Inc.
37.56%
83.82%
13.37%
-12.47%
553.14%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
10.42%
24.29%
32.26%
98.6%
210.52%
Novo Nordisk A/s
Novo Nordisk A/s
7.9%
30.89%
58.53%
230.87%
458.51%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
10.52%
25.13%
30.01%
109.26%
156.43%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Rigel Pharmaceuticals Inc
Rigel Pharmaceuticals Inc
NA
NA
-0.1
-0.07
-6.99
-0.08
NA
-0.18
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-6.46
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
29.16
29.16
1.46
44.2
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
45.83
45.83
2.36
3.5
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.9
28.9
0.53
17.11
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Rigel Pharmaceuticals Inc
Rigel Pharmaceuticals Inc
Buy
$167.5M
-55.41%
NA
-16.61%
Moderna, Inc.
Moderna, Inc.
Buy
$54.0B
553.14%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$108.8B
210.52%
29.16
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$592.1B
458.51%
45.83
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$115.1B
156.43%
28.9
39.46%

Institutional Holdings

  • Armistice Capital, LLC

    9.75%

  • BlackRock Inc

    8.66%

  • Morgan Stanley - Brokerage Accounts

    8.24%

  • Soleus Capital Management, L.P.

    5.38%

  • Vanguard Group Inc

    5.34%

  • Acadian Asset Management LLC

    3.12%

Corporate Announcements

  • Rigel Pharmaceuticals Inc Earnings

    Rigel Pharmaceuticals Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

rigel pharmaceuticals, inc., is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases.

Organization
Rigel Pharmaceuticals Inc
Employees
147
CEO
Mr. Raul R. Rodriguez
Industry
Health Technology

Discover More

FAQs